Search ACOR  Site Contents: • Types of Leukemia • Living with Leukemia • Transplants • Blood & Pathology • Survivor Stories • Medical & Cancer Links • Internet Support Email Lists • Resources • Leukemia Links Site Map Chronic Lymphocytic Leukemia  Contents Specific Treatments Chemotherapy 2CdA Brand Name: Cladribine Chlorambucil Brand Name: Leukeran Fludarabine Brand Name: Fludara Chemotherapy -- Others Chemotherapy Combinations Monoclonal Antibodies (MoAbs) Alemtuzumab Brand Name: Campath-1H Rituxamab Brand Name: Rituxan Monoclonal Antibodies -- Others Bone Marrow Transplants Spleen Treatments Clinical Trials Vaccine Trials Associated Diseases T-CELL Lymphocytic Leukemia Prolymphocytic Leukemia Richter's Syndrome Large Granulocytic Leukemia  Specific Treatments  Chemotherapy Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. CLL Trialists' Collaborative Group. J Natl Cancer Inst ; 91(10):861-8 1999. Phase III Randomized Study of Fludarabine With or Without Cyclophosphamide in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Summary Last Modified 11/2000), E-2997, Flinn IW, Eastern Cooperative Oncology Group; clinical trial, active, 12/23/1999.  2CdA Brand Name: Cladribine Cladribine in the treatment of chronic lymphocytic leukemia. Robak T.; Leuk Lymphoma 2001 Feb;40(5-6):551-64. Department of Hematology, Medical University of Lodz, Copernicus Hospital, Poland. robaktad@psk2.am.lodz.pl 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia Oral Cladribine as Primary Therapy for Patients With B-Cell Chronic Lymphocytic LeukemiaBy Gunnar Juliusson, Ilse Christiansen, Mogens M=F8rk Hansen, Stephen Johnson, Eva Kimby, Annika Elmhorn-Rosenborg, and Jan Liliemark; Journal of Clinical Oncology 14:2160-2166.  Chlorambucil Brand Name: Leukeran Chlorambucil in Indolent Chronic Lymphocytic LeukemiaGuillaume Dighiero, M.D., Ph.D., Karim Maloum, M.D., Ph.D., Bernard Desablens, M.D., et al; Volume 338:1506-1514,May 21, 1998,Number 21. The French Cooperative Group on Chronic Lymphocytic Leukemia Impact of Therapy With Chlorambucil, Fludarabine, or Fludarabine Plus Chlorambucil on Infections in Patients With Chronic Lymphocytic Leukemia: Intergroup Study Cancer and Leukemia Group B 9011. Morrison VA, Rai KR, Peterson BL, Kolitz JE, Elias L, Appelbaum FR, Hines JD, Shepherd L, Martell RE, Larson RA, Schiffer CA: J Clin Oncol 2001 Aug 15;19(16):3611-21. Veterans Affairs Medical Center, Minneapolis, MN. Does intensive treatment with high dose chlorambucil and prednisone as first line and cladribine as second line influence the survival of the patients with chronic lymphocytic leukemia? Robak T, Blonski JZ, Kasznicki M.; Leuk Lymphoma 2001 May;41(5-6):545-57. Department of Hematology, Medical University of Lodz, Copernicus Memorial Hospital, Poland. robaktad@psk2.am.lodz.pl Chlorambucil synergizes with purine analogs in inducing in vitro cytotoxicity in B-cell chronic lymphocytic leukemia, Ida Callea, Giuseppe Console, Giuseppina Sculli, Monica Filangeri, Giuseppe Messina, Fortunato Morabito Haematologica 1998,83:756-757  Fludarabine Brand Name: Fludara In vitro Sensitivity of CLL B-CELLS TO Fludarabine, 2-Chlorodeoxyadenosine, and Chlorambucil: Correlation with Clinico-Hematological and Immuniphenotypic Features  Fortunato Morabito, Caterina Stelitano, Ida Callea, Monica Filangeri, Bianca Oliva, Giuseppina Sculli, Vincenzo Callea,Francesco Nobile, Maura Brugiatelli. Related Paraneoplastic pemphigus: an association with fludarabine? Gooptu C, Littlewood TJ, Frith P, Lyon CC, Carmichael AJ, Oliwiecki S, MacWhannell A, Amagai M, Hashimoto T, Dean D, Allen J, Wojnarowska F.:Br J Dermatol 2001 Jun;144(6):1255-61.Department of Dermatology, The Oxford Radcliffe Hospital, Oxford, UK. Treatment of Refractory Chronic Lymphocytic Leukemia With Fludarabine Phosphate via the Group C Protocol Mechanism of the National Cancer Institute: Five-Year Follow-Up Report By J. Mel Sorensen, Donald A. Vena, Alfred Fallavollita, Hoo G. Chun, and Bruce D. Cheson in the Journal of Clinical Oncology 15:458-465,1997 Fludarabine Results Positive in Treating Chronic Lymphocytic Leukemia. The results of the study were presented by chief investigator Dr. Kanti Rai of the Albert Einstein College of Medicine, Long Island Jewish Medical Center, New York, at the 38th annual meeting of the American Society of Hematology, held in Orlando, Florida, December 6 - 10, 1996. Fludarabine and Cyclophosphamide in treating CLLfrom Leukemia Insights Newsletter Vol. 1, No. 4 Spring, 1996. Fludarabine and Cyclophosphamide with Filgrastim Support for the Treatment of Previously Untreated B Cell Chronic Lymphocytic Leukemia (CLL) or Indolent LymphomasJohns Hopkins Oncology Center. In Vitro Cytoxic Effect of Mitoxantrone in Combination With Fludarabine or Pentostatin in B-Cell Chronic Lymphocytic Leukemia Fortunato Morabito, Ida Callea, Giuseppe Console, Caterina Stelitano, Giuseppina Sculli, Monica Filangeri, Bianca Oliva, Caterina Musolino, Pasquale Iacopino, Maura Brugiatelli Haematologica ,September, 1977  Chemotherapy -- Others Novel therapies for chronic lymphocytic leukemia in the 21st century. Byrd JC, Waselenko JK, Keating M, Rai K, Grever MR, Semin Oncol 2000 Oct;27(5):587-97. Division of Hematology-Oncology, Walter Reed Army Medical Center, Washington, DC 20307, USA. Evaluating treatment strategies in chronic lymphocytic leukemia: use ofquality-adjusted survival analysis. Levy V, Porcher R, Delabarre F, Leporrier M, Cazin B, Chevret S; French Cooperative CLL Group; J Clin Epidemiol 2001 Jul;54(7):747-54.Departement de Biostatistique et Informatique Medicale, Hopital Saint Louis, 1 Avenue Claude Vellefaux, 75475 Paris, France. Is the CHOP regimen a good treatment for advanced CLL? Results from two randomized clinical trials. French Cooperative Group on Chronic Lymphocytic Leukemia Leukemia and Lymphoma 13(5/6): 449-456, 1994. Flavopiridol circumvents Bcl-2 family mediated inhibition of apoptosis and drug resistance in B-cell chronic lymphocytic leukaemia. PepperC, Thomas A, Hoy T, Fegan C, Bentley P., Br J Haematol 2001 Jul;114(1):70-7. Department of Haematology, Llandough Hospital, Penarth, South Glamorgan, UK. Pentostatin in chronic lymphocytic leukemia: a phase II trial of Cancer and Leukemia Group B. Dillman RO, Mick R, McIntyre OR, Journal of Clinical Oncology 7(4): 433-438, 1989.  Chemotherapy Combinations Therapeutic potential of purine analogue combinations in the treatment of lymphoid malignancies. Johnson SA, Thomas W, Hematol Oncol 2000 Dec;18(4):141-153.Department of Haematology, Taunton & Somerset Hospital, Taunton, Somerset, UK. s.a.johnson@btinternet.com A phase II study of sequential combination chemotherapy with cyclophosphamide, prednisone, and 2-chlorodeoxyadenosine in previously untreated patients with chronic lymphocytic leukemia. Tefferi A, Li CY, Reeder CB, Geyer SM, Allmer C, Levitt R, Michalak JC, Addo F, Krook JE, Witzig TE, Schaefer PL, Mailliard JA. Leukemia 2001 Aug;15(8):1171-5. Mayo Clinic, Rochester, MN 55905, USA.  Monoclonal Antibodies (MoAbs) Chemically Altered Monoclonal Antibodies Kill Cancer Cells The Monoclonal Antibodies Campath-1H and Rituximab in theTherapy of Chronic Lymphocytic Leukemia Schulz H, Winkler U, Staak JO, Engert A. Onkologie 2000 Dec;23(6):526-532. Klinik I fur Innere Medizin, Universitat zu Koln. The development of monoclonal antibody therapy in leukemias Syrigos KN, Pliarchopoulou K, Harrington KJ. Hybridoma 2001 Jun;20(3):145-8. Oncology Unit, 3rd Department of Medicine, Athens Medical School, Sotiria General Hospital, Athens, Greece. Novel treatment strategies in chronic lymphocytic leukemia. Weiss MA., Curr Oncol Rep 2001 May;3(3):217-22. Leukemia Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA.  Alemtuzumab Brand Name: Campath-1H Campath Treatment Guide Campath trial info from MDACC Clinical Trials Update: Recent Trials in Immunosuppression, David Gerber, MD. Transplant 2001: The Joint American Transplant Meeting Day 1 - May 11, 2001 Research into the development of humanized monoclonal antibodies and tolerance-inducing agents is a major thrust of research efforts to eliminate acute allograft rejection. Medscape requires you to sign in and give yourself a password. CAMPATH-1H therapy of patients with previously untreated chronic lymphocytic leukemia (CLL). Jeanette Lundin1, Magnus Bj=F6rkholm1, Fredrik Celsing1, Geoff Hale2, Victoria Hjalmar1, Eva Kimby1, Ove Tullgren1, Hermann Waldman2, h=E5kan Mellstedt1, Anders =D6sterborg1; Annals of Oncology, Vol 11, Suppl.4 October 2000, page 96. Karolinska Hospital, Stockholm, Sweden; Therapeutic Antibody Centre, Oxford, United Kingdom. New Choices for CLL, Kanti Rai,MD. 41st American Society of Hematology Annual Meeting December 7, 1999. Medscape requires you to sign in and give yourself a password. A Potential Cure Emerges for CLL: Monoclonal Antibodies Kanti Rai,MD. 41st American Society of Hematology Annual Meeting, December 6, 1999. Medscape requires you to sign in and give yourself a password. New Strategies for Chronic Lymphocytic Leukemia: Relating Biology to Therapy Hematologic Malignancies: New Biologic Approaches to Therapy [Oncology Treatment Updates - © 1999 Medscape, Inc.] Medscape requires you to sign in and give yourself a password. Immunosuppressive toxicity of CAMPATH-1H monoclonal antibody in the treatment of patients with recurrent low grade lymphoma. This is part of a Medline Search via Medscape . You'll have to sign in and give your password.  Rituxamab Brand Name: Rituxan Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Huhn D, von Schilling C, Wilhelm M, Ho AD, Hallek M, Kuse R, Knauf W, Riedel U, Hinke A, Srock S, Serke S, Peschel C, Emmerich B., Blood 2001 Sep 1;98(5):1326-1331. Department of Medicine/Hematology and Oncology, Charite Campus Virchow-Klinikum, Humboldt Universitat Berlin. Rituximab dose-escalation trial in chronic lymphocytic leukemia. O'Brien SM, Kantarjian H, Thomas DA, Giles FJ, Freireich EJ, Cortes J, Lerner S, Keating MJ. J Clin Oncol 2001 Apr 15;19(8):2165-70. Leukemia Department, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. Byrd JC, Murphy T, Howard RS, Lucas MS, Goodrich A, Park K, Pearson M, Waselenko JK, Ling G, Grever MR, Grillo-Lopez AJ, Rosenberg J, Kunkel L, Flinn IW. J Clin Oncol 2001 Apr 15;19(8):2153-64. Division of Hematology-Oncology, Department of Medicine and the Department of Clinical Investigation, Walter Reed Army Medical Center, Washington, DC, USA. byrd-2@medctr.osu.edu. High-dose rituximab therapy in chronic lymphocytic leukemia. Keating M, O'Brien S. Semin Oncol 2000 Dec;27(6 Suppl 12):86-90. Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston 77030, USA. Rituximab anti-CD20 monoclonal antibody induces marked but transient reductions of peripheral blood lymphocytes in chronic lymphocytic leukaemia patients. Ladetto M, Bergui L, Ricca I, Campana S, Pileri A, Tarella C. Med Oncol 2000 Aug;17(3):203-10. Divisione Universitaria di Ematologia - Azienda Opedaliera S. Giovanni Battista Torino, Italy. marco.ladetto@unito.it. Successful treatment and re-treatment of resistant B-cell chronic lymphocytic leukemia with the monoclonal anti-CD 20 antibody rituximab. Herold M, Schulze A, Hartwig K, Anger G., Ann Hematol 2000 Jun;79(6):332-5. 2 Medizinische Klinik, Klinikum Erfurt GmbH, Germany. mherold@tumorzentrum-erfurt.de Pentostatin and rituximab in the treatment of patients with B-cell malignancies. Drapkin R., Oncology (Huntingt) 2000 Jun;14(6 Suppl 2):25-9. Department of Medical Oncology, Florida Community Cancer Center, Clearwater, USA. chemo@intnet.net Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Hainsworth JD, Burris HA 3rd, Morrissey LH, Litchy S, Scullin DC Jr, Bearden JD 3rd, Richards P, Greco FA. Blood 2000 May 15;95(10):3052-6. Sarah Cannon Cancer Center, Centennial Medical Center, Nashville, TN 37203, USA. Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: high-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Yang H, Rosove MH, Figlin RA. Am J Hematol 1999 Dec;62(4):247-50. The Division of Hematology-Oncology, Department of Medicine, University of California, Los Angeles 90095, USA. hhyang@pol.net Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A., Blood 1999 Oct 1;94(7):2217-24. Department I of Internal Medicine, University of Cologne, Cologne, Germany. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. Byrd JC, Waselenko JK, Maneatis TJ, Murphy T, Ward FT, Monahan BP, Sipe MA, Donegan S, White CA., J Clin Oncol 1999 Mar;17(3):791-5. Division of Hematology-Oncology, Walter Reed Army Medical Center, Washington, DC 20307, USA.  Monoclonal Antibodies -- Others Arsenic and retinoic acid: towards anti-leukemia treatments targeted on the oncogene? Bexxar Effective As First-Line Therapy For Non-Hodgkin's Lymphoma Chimeric CLL-1 Antibody Fusion Proteins Containing Granulocyte-Macrophage Colony-Stimulating Factor or Interleukin-2 With Specificity for B-Cell Malignancies Exhibit Enhanced Effector Functions While Retaining Tumor Targeting Properties by Jason L. Hornick, Leslie A. Khawli, Peisheng Hu, Maureen Lynch, Peter M. Anderson, and Alan L. Epstein, Blood, Vol. 89 No. 12 (June 15), 1997: pp. 4437-4447 Techniclone's 131I LYM-1(Oncolym=AE) is an investigational treatment for non-Hodgkin's B-cell lymphoma. Clinical overview of pentostatin (Nipent) use in lymphoid malignancies. Dearden CE, Matutes E, Catovsky D., Semin Oncol 2000 Apr;27(2 Suppl 5):22-6. Academic Department of Haematology and Cytogenetics, The Royal Marsden Hospital, London, UK  Bone Marrow Transplants CD6+ donor marrow T-cell depletion as the sole form of graft-versus-host disease prophylaxis in patients undergoing allogeneic bone marrow transplant from unrelated donors. Soiffer RJ, Weller E, Alyea EP, Mauch P, Webb IL, Fisher DC, Freedman AS, Schlossman RL, Gribben J, Lee S, Anderson KC, Marcus K, Stone RM, Antin JH, Ritz J; J Clin Oncol 2001 Feb 15;19(4):1152-9. Allogeneic hematopoietic transplantation for chronic lymphocytic leukemia and lymphoma: potential for nonablative preparative regimens. Champlin R, van Besien K, Giralt S, Khouri I., Curr Oncol Rep 2000Mar;2(2):182-91. M D Anderson Cancer Center. Allogeneic and autologous transplantation for chronic lymphocytic leukemia van Besien K, Keralavarma B, Devine S, Stock W., University of Illinois at Chicago, USA, Leukemia 2001 Sep;15(9):1317-25. Bone marrow transplantation for low-grade lymphoma and chronic lymphocytic leukemia.Boussiotis VA, Freedman AS, Nadler LM; Dana Farber Cancer Institute; Semin Hematol; 36(2):209-16 1999. Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia - An Emerging Modality by Z. Steven Pavletic, MD and Philip J.Bierman, MD. Bone Marrow Transplants, A Book of Basics for Patients Susan Stewart, Blood and Marrow Transportation Information Network. Peripheral Blood Stem Cells: An Expanding Role for Allogeneic Transplant in CLLLeukemia Insights Newsletter Vol. 1, No. 4 Spring, 1996: HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia. Michallet M, Archimbaud E, Bandini G,et al. Annals of Internal Medicine 124(3): 311-315, 1996. Eradication of Polymerase Chain Reaction-Detectable Chronic Lymphocytic Leukemia Cells Is Associated With Improved Outcome After Bone Marrow Transplantation Drew Provan, Lini Bartlett-Pandite, Caroline Zwicky, Donna Neuberg, Anne Maddocks, Paolo Corradini, Robert Soiffer, Jerome Ritz, Lee M. Nadler, and John G. Gribben. BLOOD , September 15, 1996, Blood 88: 2228-2235. Eradication of polymerase chain reaction detectable immunoglobulin gene rearrangement in non-Hodgkin's lymphoma is associated with decreased relapse after autologous bone marrow transplantation CS Zwicky, AB Maddocks, N Andersen and JG Gribben; Blood 1996 88: 3314-3322. Dana-Farber Cancer Institute, Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.  Spleen Treatments Clinical and immunological evaluation of primary splenic irradiation in chronic lymphocytic leukemia: a study of 24 cases. van Mook WN, Fickers MM, Verschueren TA;Ann Hematol 2001 Apr;80(4):216-23. Department of Internal Medicine, Atrium Medical Center, Heerlen, NL. Case/control study of the role of splenectomy in chronic lymphocytic leukemia. Seymour JF, Cusack JD, Lerner SA, Pollock RE, Keating MJ; J Clin Oncol ; 15(1):52-60 1997. Splenectomy in advanced chronic lymphocytic leukemia, A single institution experience with 50 patients. Neal TF, Tefferi A, Witzig TE, et al. American Journal of Medicine 93(4): 435-440, 1992. NCI/PDQ Citation:A study of splenic irradiation in chronic lymphocytic leukemia (CLL). Guiney MJ, Liew KH, Quong GG, Cooper IA; Int J Radiat Oncol Biol Phys ; 16(1):225-9 1989.  Clinical Trials Alphabetized by Institution Phase II Study Of Antineoplaston A10 And As2-1 In Patients With Chronic Lymphocytic Leukemia S. R. Burzynski Clinic, Houston, TX. Clinical Trials being done at Johns Hopkins Medical Center Phase II Study of 9-Aminocamptothecin in Chronic Lymphocytic Leukemia (CLL) .... at Johns Hopkins Fludarabine and Cyclophosphamide with Filgrastim Support for the Treatment of Previously Untreated B Cell Chronic Lymphocytic Leukemia (CLL) or Indolent Lymphomas ... at Johns Hopkins Cancer and Leukemia Group (CALGB) Clinical Trial on CLL Long Island Jewish Medical Center. Dr. Kanti Rai, of the Rai staging process for CLL is here. Cancer Clinical Trials at Mayo Clinic. National Cancer Institute --Protocols on CLL OSU 9801: Bryostatin in Chronic Lymphocytic Leukemia Title: A Phase II Evaluation of Bryostatin-1 [NSC #339555] in Patients with Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia / NCI Protocol T97-0070 at Ohio State University Phase I Study of Bryostatin 1 in Patients With Relapsed Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia Mary L. Varterasian, Ramzi M. Mohammad, David S. Eilender, Kim Hulburd, Dorothy H. Rodriguez, Pamela A. Pemberton, James M. Pluda, Maria D. Dan, George R. Pettit, Ben D.M. Chen, and Ayad M. Al-Katib, Journal of Clinical Oncology , 1998, 16:56-62. Phase I Study of Intrathecal Mafosfamide in Patients with Refractory Chronic Lymphocytic Leukemia.... University of Pennsylvania Cancer Center Protocol Finder.  Vaccine Trials Development of herpes simplex virus-1 amplicon-based immunotherapy for chronic lymphocytic leukemia. Tolba KA, Bowers WJ, Hilchey SP, Halterman MW, Howard DF, Giuliano RE, Federoff HJ, Rosenblatt JD; Blood 2001 Jul 15;98(2):287-95. Department of Medicine, University of Rochester Cancer Center, NY, USA.  Associated Diseases  T-CELL Lymphocytic Leukemia True T-cell chronic lymphocytic leukemia: a morphologic and immunophenotypic study of 25 cases. Hoyer JD, Ross CW, Li CY, et al., Blood 86(3): 1163-1169, 1995. T-cell form of chronic lymphocytic leukaemia: a reaffirmation of its existence. Wong KF; Chan JK; Sin VC, British Journal of Haematology 1996;93(1):157-9 AD - Department of Pathology, Queen Elizabeth Hospital, Hong Kong. Human B Lymphocytes Show Greater Susceptibility to H2O2 Toxicity Than T Lymphocytes C.M. Farber, L.F. Liebes, D.N. Kanganis, and R. Silber; Journal of Immunology, Vol. 132, No. 5, May 1994 ARA-G (Compound 506): A Potent New Drug in T-Cell Diseasefrom Leukemia Insights Newsletter Vol. 1, No. 4 Spring, 1996, mD Anderson Cancer Center, University of Texas Medical Center, Houston,TX. T-cell Prolymphocytic LeukemiaEstella Matutes, MD, PhD, MRCPath, Royal Marsden Hospital and Institute of Cancer Research, London, England. Cancer Control: Journal of the Moffitt Cancer Center,5(1):19-24, 1998.  Prolymphocytic Leukemia See T-Cell Prolymphocytic Leukemia reference just above The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia I. Clinical and laboratory features of 300 patients and characterization of an intermediate group. Melo JV, Catovsky D, Galton DA, British Journal of Haematology 63: 377-387, 1986.  Richter's Syndrome Prolymphocytic transformation and Richter's Syndrome as Complications of Established CLL Primary digestive Richter's syndrome. Parrens M, Sawan B, Dubus P, Lacombe F, Marit G, Vergier B, Reiffers J, de Mascarel A, Merlio JP.;Mod Pathol 2001 May;14(5):452-7. Department of Pathology, Hopital du Haut-Leveque, Pessac, France. marie.parrens@chu-bordeaux.fr Richter's syndrome: a report on 39 patients. Robertson LE, Pugh W, O'Brien S, et al, Journal of Clinical Oncology 11(10): 1985-1989, 1993.  Large Granulocytic Leukemia Large Granular Lymphocytic Leukemia from the Leukaemia Research Fund in the UK. Large Granular Lymphocyte (LGL) Leukemia Registry, a national registry whose goals are to assist with the diagnosis of LGL leukemia and collect/analyze information on patients with LGL leukemia. Located at the University of Florida's H. Lee Moffitt Cancer Center and Research Institute , an NCI-designated cancer center. Large Granular Lymphocyte Leukemia, by Thierry Lamy, MD, and Thomas P. Loughran, Jr, MD. This article is a review of the distinctive clinical and biological characteristics of large granular lymphocyte leukemia. HOME  ::  ABOUT THIS SITE  ::  CONTACT Last updated: June 22. 2005 Copyright ©2004, 2005 ACOR, Inc. All worldwide rights reserved. ACOR and ACOR.org are registered trademarks of the Association of Online Cancer Resources, Inc.